Equities

IFR US ECM Pricings

 |  Robert Sherwood

Eupraxia Pharmaceuticals (US, biotech) ─ $70m ABB. 12.7m shares (Primary) at $5.50 versus $6.65 last sale. CANT, LSCI. Upsized from $50m. Wall cross.

Topics
Americas North America Equity Capital Structured Equity US Dollar ABBs and Block Trades Initial Public Offerings (IPO) United States Marketed Follow-Ons
Issuers
Eupraxia Pharmaceuticals Inc (EPRX.TO)